# CellSight > CellSight Technologies is a San Francisco-based biotech company advancing clinical research through innovative cell-based therapies. The company conducts clinical trials, publishes peer-reviewed scientific research, and presents findings at professional conferences. ## Overview CellSight Technologies, Inc. Headquarters: 185 Berry Street, Suite 350, San Francisco, CA 94107 Contact: contact@cellsighttechnologies.com | 650-799-1589 LinkedIn: https://www.linkedin.com/company/cellsight-technologies-inc-/ X / Twitter: https://x.com/cellsightt/ ## Business Areas - Clinical trial design, recruitment, and management - Cell-based therapy research and development - Peer-reviewed scientific publication - Conference presentations and professional knowledge sharing - Research articles and scientific updates ## Industries - Biotechnology - Life Sciences - Clinical Research - Cell Therapy - Medical Research ## Capabilities - Clinical trial recruitment (open and closed studies) - Peer-reviewed publication of scientific findings - Scientific presentations at professional conferences - Technology-driven approach to cell-based therapies - Team-based research with experts in cell biology ## Keywords CellSight, CellSight Technologies, cell therapy, cell-based therapy, clinical trials, biotech, biotechnology, life sciences, scientific research, publications, presentations, San Francisco, clinical research ## Pages Main site pages. - [Technology](/technology) - [Clinical Trials](/clinical-trials) - [Publications](/publications) - [About Us](/about) ## Clinical Studies Clinical trials and research studies conducted by CellSight Technologies. - [Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer ](): Open for recruitment - [[18F]F-AraG PET imaging of Non Small Cell Lung Cancer patients undergoing checkpoint inhibitor immunotherapy](): Open for recruitment - [Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG ](): Open for recruitment - [Test-retest Evaluation of [18F]F-AraG PET](): Open for recruitment - [A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer (SHARP)](): Open for recruitment - [A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors](): Open for recruitment - [ [18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients](): Open for recruitment - [Imaging of T-cell Activation With [18F]F-AraG in Advanced Non-Small Cell Lung Cancer (NSCLC)](): Open for recruitment - [Imaging Immune Activation in COVID-19](): Open for recruitment - [18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma](): Open for recruitment - [ [18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer (ATTAIN)](): Open for recruitment - [PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)](): Closed - [Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab](): Closed - [Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer](): Closed - [Imaging Immune Activation in HIV by PET-MR](): Open for recruitment - [Detection of Graft Versus Host Disease With [18F]F-AraG](): Closed - [Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1](): Closed - [Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)](): Closed - [ [18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy](): Closed - [Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans](): Closed ## Publications Peer-reviewed scientific publications authored or co-authored by CellSight researchers. - [[18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy](https://jnm.snmjournals.org/content/early/2024/10/24/jnumed.124.268253) - [Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer](https://link.springer.com/article/10.1007/s00259-024-06931-3) - [Enrichment of novel CD3+F4/80+ cells in brown adipose tissue following adrenergic stimulation](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1455407/full ) - [A feasibility study of [18F]F-AraG positron emission tomography (PET) for cardiac imaging - myocardial viability in ischemia-reperfusion injury model](https://link.springer.com/article/10.1007/s11307-024-01932-y) - [Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection](https://www.science.org/doi/10.1126/scitranslmed.adk3295?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) - [[18F]F-AraG imaging reveals association between neuroinflammation and brown- and bone marrow adipose tissue](https://www.nature.com/articles/s42003-024-06494-x) - [Total-Body Dynamic Imaging and Kinetic Modeling of [18F]F-AraG in Healthy Individuals and a Non–Small Cell Lung Cancer Patient Undergoing Anti–PD-1 Immunotherapy](https://jnm.snmjournals.org/content/65/9/1481.long) - [The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors.](https://www.frontiersin.org/articles/10.3389/fimmu.2022.1113924/full) - [Biodistribution of a Mitochondrial Metabolic Tracer, 18F-FAraG, in Healthy Volunteers.](https://www.hindawi.com/journals/moi/2022/3667417/) - [Longitudinal imaging of T-cells and inflammatory demyelination in a preclinical model of multiple sclerosis using 18F-FAraG PET and MRI.](https://pubmed.ncbi.nlm.nih.gov/33837066/) - [18F-FAraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy.](https://pubmed.ncbi.nlm.nih.gov/33158906/) - [Imaging of activated T cells as an early predictor of immune response to anti-PD-1 therapy.](http://cancerres.aacrjournals.org/content/early/2019/05/07/0008-5472.CAN-19-0267.long) - [A PET imaging strategy to visualize activated T cells in acute graft-versus-host disease elicited by allogenic hematopoietic cell transplant.](http://cancerres.aacrjournals.org/content/77/11/2893.long) - [In vivo PET imaging of the activated immune environment in a small animal model of inflammatory arthritis.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480631/) - [Synthesis of 2'-deoxy-2'-[18F]fluoro-9-β-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET](https://link.springer.com/article/10.1007%2Fs11307-010-0414-x) ## Presentations Scientific presentations and conference contributions from CellSight. - [SNNMI 2021 poster presentation.](https://jnm.snmjournals.org/content/62/supplement_1/1281) - [SITC 2021 poster presentation.](https://jitc.bmj.com/content/9/Suppl_2/A52) - [IBA Radiopharma Webinar 2019 The role of PET imaging in Immuno-Oncology.](https://www.gotostage.com/channel/c91227af67ff4be2ad68ba39372dabdb/recording/a9bc8a273e68482c9ba4a8e3d5ed2ab5/watch?source=CHANNEL) ## Notes - The site is in English only. - Clinical trial studies are listed on /clinical-trials. - Scientific publications and presentations are listed on /publications.